https://doi.org/10.4081/hmr.v2i13.495

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006
Published: June 10, 2009
Abstract Views: 215
PDF: 698
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Duvic
support@pagepress.org
Bexarotene (Targretin® oral capsules) is the first RXR selective retinoid rexinoid, approved for all stages of cutaneous T-cell lymphoma (CTCL). Two phase II clinical trials were conducted in early and advanced patients with CTCL (Mycosis Fungoides (MF) and Sezary Syndrome (SS). The overall response rate RR was 45% at an optimal dose of 300 mg/m2/day. Higher response rates were seen in earlier patients (54%) and at higher doses 300 mg/m2/day. Hypertriglyceridemia was reported in 79% of the patients and therefore we always administer liipid lowering agents (LLA) to optimize the clinical response. Statins (inhibitors of HMG-CoA reductase) may modulate class II MHC expression and T-cell responses.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Duvic, M. (2009). Optimizing bexarotene therapy for cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.495
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).